Compare RDZN & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RDZN | DERM |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | 308 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.7M | 135.3M |
| IPO Year | N/A | 2021 |
| Metric | RDZN | DERM |
|---|---|---|
| Price | $1.79 | $6.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | ★ 784.6K | 213.5K |
| Earning Date | 02-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $61,858,000.00 |
| Revenue This Year | $33.77 | $39.72 |
| Revenue Next Year | $51.46 | $63.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.20 |
| 52 Week Low | $0.81 | $4.31 |
| 52 Week High | $2.56 | $9.56 |
| Indicator | RDZN | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 67.00 |
| Support Level | $1.69 | $4.85 |
| Resistance Level | $1.95 | $7.66 |
| Average True Range (ATR) | 0.25 | 0.35 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 37.35 | 77.66 |
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.